Eva Galvan

Ferroptosis and Radiotherapy in Lung Cancer

Prem C. Patel, Eva Galvan

BACKGROUND: Lung cancer (LC) is a leading cause of cancer mortality worldwide. While radiotherapy (RT) has been a lasting cornerstone of LC management, there are concerns due to tumor radioresistance and unintended damage to surrounding healthy tissue. Ferroptosis is a recently described …

us (code pays fourni par la source)

CTNI-67. PHASE 1 MULTICENTER STUDY OF MULTIPLE DOSES OF RHENIUM (186RE) OBISBEMEDA (REYOBIQ) FOR LEPTOMENINGEAL METASTASES: RATIONALE, DESIGN, AND PRELIMINARY COHORT 1 DATA

Andrew Jacob Brenner, Priya Kumthekar, Michael Schulder, Eva Galvan et autres

Abstract Leptomeningeal metastases (LM) are a devastating complication of solid tumors with limited treatment options and poor survival outcomes. Reyobiq, a nanoliposome-encapsulated beta-emitting radionuclide, offers focused radiation delivery to the cerebrospinal fluid (CSF) with a 2 mm beta particle path length and …

us (code pays fourni par la source)

Sociodemographic Barriers to Successful Implementation of Optune in Glioblastoma Multiforme Patients

Clark L. Anderson, Shraddha Mahesh Dalwadi, Eva Galvan, Joel Edmund Michalek

OBJECTIVES: Tumor-treating fields (TTFields), or Optune, is a therapy that utilizes electrical fields to stagnate tumor growth in patients with glioblastoma multiforme (GBM). This retrospective review of a single institution's experience identifies sociodemographic hurdles to patient compliance, initiation, and continuation with TTFields. …

us (code pays fourni par la source)

Anaplastic meningioma in a 6-year-old with somatic YAP1::MAML2 fusion and multiple endocrine neoplasia type 4 (MEN4) syndrome

Lauren Desrosiers, John H. Lee, Izabela Tarasiewicz, Andrea Gilbert et autres

us (code pays fourni par la source)

Pleomorphic xanthoastrocytoma with anaplasia and BEND5-NTRK2 fusion in a young adult with a history of cranial radiation for childhood rhabdomyosarcoma

Julie E. Fischer, Andrea Gilbert, Eva Galvan, Achint K. Singh et autres

Julie M Fischer, MD, Andrea R Gilbert, DO, Eva M Galvan, MD, Achint K Singh, MD, John R Floyd, MD, FAANS, Shafqat Shah, MD; Pleomorphic xanthoastrocytoma w

us (code pays fourni par la source)

Increasing Diversity in Academic Medicine Via a Strategic Intermural Housestaff Leadership Development Program

Eva Galvan, Christina E. Ahn, Marissa Hansen, Vanessa Evoh et autres

PROBLEM: By 2055, the United States will no longer have a single race or ethnic majority. As the nation's demographics change, the field of medicine must also change to meet the needs of diverse patients. APPROACH: In 2013, UT Southwestern Medical Center …

us (code pays fourni par la source)

Anaplastic Meningioma in a 6-Year-Old with Somatic Yap1::Maml2 Fusion and Multiple Endocrine Neoplasia Type 4 (Men4) Syndrome

Lauren Desrosiers, John H. Lee, Izabela Tarasiewicz, Andrea Gilbert et autres

us (code pays fourni par la source)

Retrospective Review of the Factors Limiting Optune Initiation in GBM patients

L. Peña, Carryn M. Anderson, Mohit Shiv Agarwal, Eva Galvan et autres

us (code pays fourni par la source)

Pharmacologic tumor PDL1 depletion as a novel approach to overcome treatment resistance

Clare Murray, Haiyan Bai, Carlos Oscar Ontiveros, Paige Blinkiewicz et autres

Abstract Tumor surface PDL1 canonically engages immune cell PD1 to inhibit anti-tumor immunity. However, PDL1 also mediates tumor-intrinsic pathologic signals, including promoting the DNA damage response (DDR) and suppressing immunogenic STING. Genetic tumor PDL1 depletion (CRISPR/Cas9, shRNA) induces novel treatment vulnerabilities that …

us, gb (code pays fourni par la source)

453 Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities

Clare Murray, Haiyan Bai, Anand V. R. Kornepati, Carlos Ontiveros et autres

Background Canonical tumor surface PDL1 signals to PD1 on immune cells to evade antitumor immunity are well-defined.1 However, tumor-intrinsic PDL1 mediates additional pathologic signals.2-5 Our lab recently showed that tumor PDL1 promotes homologous recombination DNA damage repair and ATM/Chk2 DNA damage sensing. …

lb, us (code pays fourni par la source)

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents

Clare Murray, Eva Galvan, Carlos Ontiveros, Yilun Deng et autres

The interaction between tumor surface-expressed PDL1 and immune cell PD1 for the evasion of antitumor immunity is well established and is targeted by FDA-approved anti-PDL1 and anti-PD1 antibodies. Nonetheless, recent studies highlight the immunopathogenicity of tumor-intrinsic PDL1 signals that can contribute to …

us (code pays fourni par la source)

Trauma-induced lung injury is associated with infiltration of activated TLR expressing myeloid cells

Meenakshi Rani, Shannon Sayyadioskoie, Eva Galvan, Susannah E. Nicholson et autres

us (code pays fourni par la source)